Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mechanisms of resistance and correlation between pre-treatment co-alterations and p-prognosis to osimertinib in chemo-naïve advanced non-small cell lung cancer.
Tamiya A, Osuga M, Harada D, Isa SI, Taniguchi Y, Nakamura K, Mizumori Y, Shinohara T, Yanai H, Nakatomi K, Oki M, Mori M, Kuwako T, Yamazaki K, Tamura A, Ando M, Koh Y. Tamiya A, et al. Among authors: nakatomi k. Lung Cancer. 2024 Sep;195:107917. doi: 10.1016/j.lungcan.2024.107917. Epub 2024 Aug 3. Lung Cancer. 2024. PMID: 39116552 Free article.
The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment.
Sueoka-Aragane N, Nakashima C, Yoshida H, Matsumoto N, Iwanaga K, Ebi N, Nishiyama A, Yatera K, Kuyama S, Fukuda M, Ushijima S, Umeguchi H, Harada D, Kashiwabara K, Suetsugu T, Fujimoto N, Tanaka F, Uramoto H, Yoshii C, Nakatomi K, Koh G, Seki N, Aoe K, Nosaki K, Inoue K, Takamori A, Kawaguchi A. Sueoka-Aragane N, et al. Among authors: nakatomi k. Cancer Med. 2021 Jun;10(12):3873-3885. doi: 10.1002/cam4.3929. Epub 2021 May 12. Cancer Med. 2021. PMID: 33982444 Free PMC article.
Prophylactic treatment of dacomitinib-induced skin toxicities in epidermal growth factor receptor-mutated non-small-cell lung cancer: A multicenter, Phase II trial.
Iwasaku M, Uchino J, Chibana K, Tanzawa S, Yamada T, Tobino K, Uchida Y, Kijima T, Nakatomi K, Izumi M, Tamiya N, Kimura H, Fujita M, Honda R, Takumi C, Yamada T, Kaneko Y, Kiyomi F, Takayama K. Iwasaku M, et al. Among authors: nakatomi k. Cancer Med. 2023 Jul;12(14):15117-15127. doi: 10.1002/cam4.6184. Epub 2023 Jun 3. Cancer Med. 2023. PMID: 37269194 Free PMC article. Clinical Trial.
Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance status.
Taniguchi Y, Tamiya A, Osuga M, Harada D, Isa SI, Nakamura K, Mizumori Y, Shinohara T, Yanai H, Nakatomi K, Oki M, Mori M, Kuwako T, Yamazaki K, Tamura A, Ando M, Koh Y. Taniguchi Y, et al. Among authors: nakatomi k. BMC Pulm Med. 2024 Aug 24;24(1):407. doi: 10.1186/s12890-024-03212-5. BMC Pulm Med. 2024. PMID: 39182046 Free PMC article.
Phase II study of ramucirumab and docetaxel for previously platinum-treated patients with non-small cell lung cancer and malignant pleural effusion (PLEURAM study).
Takemoto S, Fukuda M, Ogata R, Senju H, Sugasaki N, Nakatomi K, Tomono H, Suyama T, Sasaki E, Matsuo M, Akagi K, Hayashi F, Dotsu Y, Ono S, Honda N, Taniguchi H, Gyotoku H, Ikeda T, Nagashima S, Soda H, Kinoshita A, Mukae H. Takemoto S, et al. Among authors: nakatomi k. Transl Lung Cancer Res. 2024 Oct 31;13(10):2673-2682. doi: 10.21037/tlcr-24-508. Epub 2024 Oct 24. Transl Lung Cancer Res. 2024. PMID: 39507035 Free PMC article.
71 results